Comparative Pharmacology
Head-to-head clinical analysis: TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE versus ZYNLONTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE versus ZYNLONTA.
TIPIRACIL HYDROCHLORIDE AND TRIFLURIDINE vs ZYNLONTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Trifluridine is a thymidine-based nucleoside analog that incorporates into DNA, interfering with DNA synthesis and function. Tipiracil hydrochloride inhibits thymidine phosphorylase, preventing trifluridine degradation and increasing its systemic exposure.
ZYNLONTA (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) consisting of a humanized anti-CD19 monoclonal antibody conjugated via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxin. Upon binding to CD19-expressing cells, the conjugate is internalized and the linker is cleaved, releasing the PBD dimer, which crosslinks DNA and induces cell death.
35 mg/m² orally twice daily on days 1-5 and 8-12 of each 28-day cycle. Maximum dose: 80 mg per dose.
0.15 mg/kg intravenously every 3 weeks, up to a maximum of 9 mg per dose, until disease progression or unacceptable toxicity.
None Documented
None Documented
The terminal elimination half-life of trifluridine is approximately 1.4 to 2.1 hours. For tipiracil, the half-life is about 2.1 to 3.3 hours. The short half-lives necessitate twice-daily dosing to maintain therapeutic concentrations.
Terminal elimination half-life (t½) is approximately 0.6 hours (range 0.3–1.0 hours) for the intact antibody–drug conjugate, reflecting rapid clearance; the unconjugated payload (SG3199) has a longer t½ of approximately 1–2 hours.
Trifluridine is primarily eliminated via metabolism and renal excretion. Approximately 29% of the trifluride dose is recovered in urine as trifluridine and its metabolites, with less than 3% as unchanged drug. Fecal excretion accounts for about 38% of the dose, mainly as metabolites. Tipiracil is predominantly excreted renally (about 55% as unchanged drug and metabolites) and fecally (about 19%).
Primarily eliminated via biliary/fecal route (approximately 71% of administered dose recovered in feces as unchanged drug), with renal excretion accounting for a minor fraction (<10% of dose as unchanged drug in urine).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent